Atrial premature beats are frequently diagnosed during pregnancy (PR); supraventricular tachycardia (SVT) (atrial tachycardia, AV-nodal reentrant tachycardia, circus movement tachycardia) is less frequently diagnosed.
INTRODUCTION

MATERNAL ARRHYTHMIAS DURING PREGNANCY
Incidence and first manifestation
Supraventricular or ventricular tachyarrhythmias can become more frequent during pregnancy or they may develop for the first time. [13] An increase in the incidence of cardiac arrhythmias has been reported during pregnancy in patients with and without identifiable heart disease. [14] New onset or increased frequency of supraventricular or ventricular tachyarrhythmias was reported during pregnancy in patients with preexcitation syndromes or other causes. [15] Increased sympathetic activity during pregnancy has been proposed as a mechanism for increased incidence of arrhythmias. [1, 16] Occurrence of cardiac tachyarrhythmias may also be related to physiological changes occurring during pregnancy, such as increased heart rate, decreased peripheral resistance and increased stroke volume.
[17] Lee et al. [18] reported a low risk of first onset of paroxysmal supraventricular tachycardia (SVT) during pregnancy with an incidence of 4%. In the 107 patients with accessory pathway-mediated tachycardia, 7 patients had the first onset of tachycardia during pregnancy. In the 100 patients with atrioventricular-nodal reentrant tachycardia, one patient had the first onset of tachycardia during pregnancy. Ventricular tachycardia (VT) is rarely observed during pregnancy. Nakagawa et al. [19] studied 11 pregnant women who experienced new-onset ventricular arrhythmias during pregnancy. The onset of their first episode of ventricular arrhythmia was distributed equally over the three trimesters. The authors concluded that various hemodynamic and neurohumoral changes associated with pregnancy play an important role in ventricular arrhythmogenesis. [19] In women with well-known recurrent episodes of SVTs, 14 of 63 patients (22%) with tachycardia in the pregnant and nonpregnant periods had exacerbation of symptoms during pregnancy.
[18] Similar observations have been reported by others. [20, 21] Types of arrhythmias Shotan et al.[14] assessed the relationship between symptoms and cardiac arrhythmias in 110 consecutive pregnant patients without evidence of heart disease referred for evaluation of palpitations (group G I), dizziness and syncope. These patients were compared with 52 consecutive pregnant patients referred for evaluation of symptomatic functional precordial murmur (group G II). Sinus bradycardia (heart rate <60/min) recorded during Holter monitoring (1% in G I, 2% in G II; P = ns) and sinus tachycardia (heart rate >100/min) (9% in G I, 10% in G II; P = ns) were relatively rare, whereas there was a high frequency of sinus arrhythmias in both groups (61% in G I, 69% in G II; P = ns). Isolated atrial premature beats (APB) were seen in 56% in G I and 58% in G II (P = ns), complex APBs (5% GI and 0% G II patients, P = ns) or SVT (1% in G I, 6% in G II, P = ns) were observed rarely. Isolated ventricular premature beats (PVC) were recorded in 49% G I and 40% G II patients (P = ns), whereas the incidence of multifocal PVCs was higher in G I (12%) than in G II (2%) (P < 0.05). Ventricular tachycardia (VT) or ventricular fibrillation (VF) were not recorded in any of the patients. [14] 
Diagnostic procedures
Before initiating therapy, it is important to correctly diagnose the type and mechanism of the underlying 
FETAL ARRHYTHMIAS DURING PREGNANCY
Incidence
Intrauterine, all types of arrhythmias can occur. They are frequently intermittent and may disappear until delivery or the neonatal period. [22, 23] Fetal arrhythmias can carry a significant risk of morbidity and mortality;
especially, when arrhythmias cause hydrops fetalis, where it is associated with fetal death or neurological damage. [24, 25] In 2003, in the Swiss prospective FETCH-study, there was an 11% incidence of arrhythmias in 433 fetal echocardiographic examinations (http://www.neonat.ch). Among these arrhythmias, supraventricular premature beats were present in 79%, atrial fibrillation (AF) in 2%, SVT in 15% and atrio-ventricular blocks in the remaining 4%. It has been reported that AV-nodal reentrant tachycardia, ectopic atrial tachycardia or atrial flutter (AFlut) are serious and threatening rhythm disorders in the human fetus. [26] A fetal tachycardia of a moderate high rate with 1 : 1 retrograde conduction and poor cardiac tolerance can be due to a junctional ectopic tachycardia (JET). [27] In contrast to arrhythmias with a heart rate >100/min, high-degree AV-block with persistent fetal bradycardia can occur either in normal hearts or those with structural diseases. [28, 29] There is a poor prognosis when high-degree AV block is associated with congenital heart disease. In some cases, the fetal congenital AV-block is caused by QT-prolongation or immune-diseases mediated. [30] 
Diagnostic procedures
The 
ACUTE THERAPY OF SUPRAVENTRICULAR ARRHYTHMIAS IN THE PREGNANT WOMAN
Narrow-QRS complex tachycardia
Narrow-QRS tachycardia is a cardiac rhythm with a rate faster than 100 beats/min and a QRS duration of <0.12 s. [34] The patient with narrow-QRS tachycardia usually seeks medical attention because of palpitations, lightheadedness, shortness of breath or anxiety. In many patients with a narrow-QRS complex tachycardia, the tachycardia rate is very high (180-240 beats/ min) and therefore, after onset of the tachycardia the patient will arrive very soon thereafter in an intensive care unit for diagnosis and treatment. The definitive diagnosis of a Figure 1 ]. Specific antiarrhythmic drugs should be avoided whenever possible in these conditions, because all commonly used antiarrhythmic drugs cross the placenta and may develop serious side effects to the fetus. The advantage of adenosine (9-18 mg iv as bolus)
relative to intravenous calcium antagonists or beta-blockers relates to its rapidity of onset and short half-life. [35] In addition, the present report on human clinical experience with adenosine during pregnancy indicates no teratogenicity or other adverse effects to the fetus and it is as effective in terminating SVT (efficacy rates >90%)
in pregnant women as it is in patients who are not pregnant. Longer acting agents (intravenous calcium channel blockers or cardioselective beta-blocking agents) are of limited value because of a possible increase of hypotensive and/or bradycardiac effects. [36] In patients with AV-nodal reentrant tachycardia, intravenous calcium channel blockers are acceptable drugs. The greatest experience has accrued with verapamil (10 mg iv over 3 min, 5 mg iv in woman with previous beta-blocker therapy and/or hypotension (RR syst < 100 mmHg).
Clinical studies of verapamil in pregnant women have not demonstrated adverse effects on either the patient or the fetus. However, intravenous administration of verapamil carries a risk of precipitating maternal hypotension and secondary hypoperfusion. In addition, verapamil is capable of causing fetal bradycardia, high-degree AV block and hypotension. Pregnancy is also related to an increased frequency of arrhythmias in previously asymptomatic patients with Wolff-Parkinson-White syndrome. [37] Therefore, ajmaline (50-100 mg iv over 5 min) is an alternative antiarrhythmic drug in emergencies, particularly in patients with accessory pathways; this has been well known for many years in nonpregnant patients with circus movement tachycardia. [38] There are no sufficient data regarding teratogenicity or other adverse effects to the fetus when ajmaline is used.
Therefore, ajmaline should be avoided during the first trimester and only used when other therapeutic alternatives are not present or even unsuccessful. If vagal maneuvers and/or unspecific or specific drugs are ineffective to terminate SVT, direct current (DC) cardioversion (10-50 J) is well tolerated and effective to terminate the arrhythmia. [39] In a very few pregnant patients with otherwise untreatable tachycardia, either by drugs or by DC current energy, a 'rescue' radiofrequency ablation is indicated and possible with excellent results and shows no serious side effects for the pregnant woman or the fetus. [40] 
ACUTE THERAPY OF VENTRICULAR ARRHYTHMIAS IN THE PREGNANT WOMAN
One of the most important problems in intensive care, emergency medicine and cardiac rhythmology are to take care of pregnant patients with recurrent VT, ventricular flutter or VF. Management of cardiac arrest due to life-threatening ventricular tachyarrhythmias is essential to prevent sudden cardiac death in the mother and the fetus. However, treatment of the underlying arrhythmia requires a correct diagnosis. This is possible in the majority of patients using a 12-lead surface electrocardiogram.
Wide-QRS complex tachycardia
Since a drug given for the treatment of SVT may be deleterious to a patient with VT, the differential diagnosis of a broad QRS tachycardia is critical. Wide-QRS complex tachycardias (QRS duration >0.12 s) often pose a difficult diagnostic and therapeutic problem. [34] Errors are made because emergency care professionals wrongly consider VT unlikely if the patient is young and hemodynamically stable, and they are often unaware of the ECG findings that quickly and accurately distinguish VT in more than 90% of cases. To make the right diagnosis, it is ideal to have a 12-lead ECG. Diagnostic clues for differentiation of VT from SVT are findings in lead V1 and V6; in addition, a QRS of 0.14 s or more favors a diagnosis of VT. There are several possible mechanisms of wide-QRS complex tachycardia.
Although sustained (duration >30 s) VT is rare in pregnant women, there are some reports that VT (when occurring) originates in the patient with a normal heart mainly from the right ventricular outflow tract. [34] Idiopathic left VT also occurs in pregnant patients with structurally normal hearts. In contrast to pregnant patients with normal left ventricular function, there is a poor prognosis when VT is associated with structural heart disease. [10] For acute treatment differentiation of VT -hemodynamically unstable or stable -is essential.
If at any time VT is becoming unstable or if there is evidence of fetal compromise, DC countershock (50-100 J)
should be delivered immediately [ Figure 1 ]. If a DC shock of 50-100 J is unsuccessful, higher energy is mandatory (100-360 J) and without any risk for mother and children. 'Conservative' therapy is indicated in any patient with sustained VT and stable hemodynamics [ Figure 2 ]. Acute therapy should start with intravenous procainamide or with ajmaline (50-100 mg iv over 5 min). Procainamide appears to be equally safe, is well tolerated and has not been associated with teratotoxicity, whereas the potential risk of ajmaline during pregnancy is unclear and administration should be limited for emergencies. [10] Another potential antiarrhythmic Emergency therapy of maternal and fetal arrhythmias during pr... http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2884446/?repor...
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1/4/12 5:46 AM drug is lidocaine, which is not known to be teratogenic. Although several studies have shown some adverse effects (increase in myometrial tone, decrease in placental blood flow, fetal bradycardia), its use during the early months of pregnancy is not associated with a significant increase in the incidence of fetal defects. [39] Class III antiarrhythmic agents (such as sotalol, amiodarone) are very effective drugs in patients with ventricular tachyarrhythmias. During pregnancy, both drugs are of limited value: sotalol appears to be relatively safe, although there is a 3-5% risk of developing polymorphic or torsade de pointes tachycardia []. In addition, the β-adrenergic properties of sotalol must be considered. Amiodarone is well known for its many and serious side effects both for the mother and the fetus, including hypothyroidism, growth retardation and premature delivery. [45, 46] There is limited experience of amiodarone usage during pregnancy and thus treatment with this drug should be reserved for life-threatening conditions. [47] Magnesium is another drug with antiarrhythmic properties, particularly in patients with torsade de pointes tachycardia due to QT prolongation. It is known for a long time that in emergency circumstances, magnesium sulfate (dosage 1 to 2 g iv) is effective to treat and to suppress life-threatening ventricular tachyarrhythmias and should be administered over 1 to 2 min. Although this drug is associated with few side effects, maternal hypothermia and fetal bradyarrhythmias have been observed. [48] In a few cases, verapamil is effective in pregnant women with right/left ventricular outflow tachycardia. [49] Ventricular fibrillation and ventricular flutter metoprolol. In contrast, β2-blocking agents has been associated in some cases with reduced uteroplacental perfusion and/or fetal growth retardation, and hence should not be chosen for treating VPBs. [44] There is no indication for treatment with class III antiarrhythmic drugs due to their side effects and risk for proarrhythmia. [14] Figures and Tables 
